This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CTI BioPharma Beheer

Beheer criteriumcontroles 3/4

De CEO CTI BioPharma is Adam Craig, benoemd in Mar2017, heeft een ambtstermijn van 6.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.59M, bestaande uit 14.3% salaris en 85.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.022% van de aandelen van het bedrijf, ter waarde $ 267.56K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6 jaar en 6.3 jaar.

Belangrijke informatie

Adam Craig

Algemeen directeur

US$4.6m

Totale compensatie

Percentage CEO-salaris	14.3%
Dienstverband CEO	6.3yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	6yrs
Gemiddelde ambtstermijn bestuur	6.3yrs

Recente managementupdates

Recent updates

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

Aug 17

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

Aug 08

CTI BioPharma: Approval Is Great, Now There's The Follow Through

Jul 19

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

Jul 07

Analyse CEO-vergoeding

Hoe is Adam Craig's beloning veranderd ten opzichte van CTI BioPharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2023	n/a	n/a	-US$69m
Dec 31 2022	US$5m	US$657k	-US$93m
Sep 30 2022	n/a	n/a	-US$112m
Jun 30 2022	n/a	n/a	-US$121m
Mar 31 2022	n/a	n/a	-US$118m
Dec 31 2021	US$2m	US$633k	-US$98m
Sep 30 2021	n/a	n/a	-US$76m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$58m
Dec 31 2020	US$3m	US$615k	-US$52m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$44m
Mar 31 2020	n/a	n/a	-US$41m
Dec 31 2019	US$2m	US$595k	-US$40m
Sep 30 2019	n/a	n/a	-US$31m
Jun 30 2019	n/a	n/a	-US$36m
Mar 31 2019	n/a	n/a	-US$36m
Dec 31 2018	US$3m	US$564k	-US$29m
Sep 30 2018	n/a	n/a	-US$45m
Jun 30 2018	n/a	n/a	-US$42m
Mar 31 2018	n/a	n/a	-US$29m
Dec 31 2017	US$6m	US$434k	-US$45m

Compensatie versus markt: De totale vergoeding ($USD 4.59M ) Adam } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.15M ).

Compensatie versus inkomsten: De vergoeding van Adam is gestegen terwijl het bedrijf verliesgevend is.

CEO

Adam Craig (57 yo)

6.3yrs

Tenure

US$4,592,646

Compensatie

Dr. Adam R. Craig, M.D., Ph D., M.B.A., has been the Chief Executive Officer, President and Director of CTI BioPharma Corp. since March 20, 2017 and serves its Interim Chief Medical Officer. Dr. Craig serv...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Adam Craig	President	6.3yrs	US$4.59m	0.022% $ 267.6k
David Kirske	Executive VP	5.8yrs	US$1.47m	0.013% $ 155.7k
James Fong	Executive VP & Chief Commercial Officer	no data	US$597.30k	0.0027% $ 32.4k
Ed Bell	Senior Director of Investor Relations	15yrs	geen gegevens	geen gegevens
Bruce Bennett	Senior Vice President Global Pharmaceutical Operations	no data	geen gegevens	geen gegevens
John Volpone	Executive VP & Chief of Staff	no data	geen gegevens	geen gegevens
Jennifer Smith	Senior Vice President of Biometrics	4.6yrs	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CTIC is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Adam Craig	President	6.3yrs	US$4.59m	0.022% $ 267.6k
Diane Parks	Independent Director	1.8yrs	US$301.12k	0% $ 0
Daniel Von Hoff	Chairman of Scientific Advisory Board	9.9yrs	geen gegevens	geen gegevens
Laurent Fischer	Independent Chairman of the Board	5.9yrs	US$352.12k	0% $ 0
David Parkinson	Independent Director	6yrs	US$317.62k	0% $ 0
Matthew Perry	Independent Director	7.4yrs	US$303.62k	0.033% $ 392.1k
Reed Tuckson	Independent Director	11.8yrs	US$319.12k	0.037% $ 442.1k
Michael Metzger	Independent Director	6.4yrs	US$330.62k	0% $ 0

6.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CTIC wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

This company listing is no longer active

CTI BioPharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CTI BioPharma Corp. Announces Executive Changes

CTI BioPharma Corp., Annual General Meeting, Jun 01, 2022

CTI BioPharma Corp. appoints James K. Fong as senior vice president and chief commercial officer

Recent updates

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from NASDAQ Composite Index

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P TMI Index

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Comp Value Index

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

CTI BioPharma Corp. to Report Q3, 2022 Results on Nov 07, 2022

CTI BioPharma Corp. Announces Executive Changes

CTI BioPharma Corp. Announces Presentation of New Anemia Benefit Data from Pacritinib Program At the Society of Hematologic Oncology Tenth Annual Meeting

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

CTI BioPharma Corp. to Report Q2, 2022 Results on Aug 08, 2022

CTI BioPharma: Approval Is Great, Now There's The Follow Through

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset

CTI BioPharma Corp., Annual General Meeting, Jun 01, 2022

National Comprehensive Cancer Network Recommends CTI BioPharma Corp.'s VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms

CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. appoints James K. Fong as senior vice president and chief commercial officer

CTI BioPharma Corp. Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

CTI BioPharma: A Speculative Buy Into The PDUFA Date

CTI BioPharma: Long And Troubled History, Finally Approaching Approval

CTI BioPharma Corp. Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis with Severe Thrombocytopenia

CTI BioPharma Corp. Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis

FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA

CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. to Report Q4, 2020 Results on Mar 17, 2021

CTI BioPharma: Accelerated Approval Pathway Looks Attractive

Cti Biopharma Corp. Announces Publication of Article Highlighting Pacritinib Data from the Pac203 Phase 2 Study in Myelofibrosis in Blood Advances

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. to Report Q3, 2020 Results on Nov 10, 2020

CTI BioPharma Corp. Initiates Rolling Submission of New Drug Application for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma Corp. Contemplates Bankruptcy

Earnings released

New 90-day high - US$1.60

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd